上周三,诺和诺德公布 2025 年第一季度财报,司美格鲁肽销售额达 557.76 亿丹麦克朗(约合 84.1 亿美元,约合人民币 608 亿元),同比增长 32%,占诺和诺德总营收的 71%。[1] 而根据默沙东此前公布的第一季度财报,去年销售额全球 TOP 1 的 K 药,营收达 72.05 亿美元。[2] 图源:参考资料 2 2025 年第一局,司美正式反超 K 药,登上全球“药王”的宝座。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.